Recon: Supreme Court rejects lawsuit challenging abortion pill deliveries; Pfizer’s Duchenne muscular dystrophy gene therapy falters in late-stage study

• Supreme Court unanimously rejects challenge to mailed abortion pills (STAT) (Reuters)
• Abortion pill still under legal threat despite US Supreme Court ruling (Reuters)
• Was the FDA Panel Right to Recommend Against MDMA Approval? (Medpage Today)
• Pfizer’s gene therapy for Duchenne muscular dystrophy fails in Phase 3 trial (STAT)
• Biden and Trump are fighting to claim credit for $35 insulin. It was actually a pharma giant’s idea (STAT)
• Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease (Endpoints)
• J&J returns bispecific T cell engager to Xencor, reducing scope of partnership (Endpoints)
• US Southern Baptists condemn IVF procedure (Reuters)
• U.S. healthcare spending rises to $4.8 trillion in 2023, outpacing GDP (Reuters)

• Alchem accused of pharma price fixing by EU watchdog (Reuters)
• Global health leader critiques ‘ineptitude’ of U.S. response to bird flu outbreak among cows (STAT)
• Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried (STAT)
• EU Regulators Clarify How ‘Super-Grouping’ Under New Variations Rules Will Work (Pink Sheet)
• Ireland Should Look To UK & Denmark To Raise Its Clinical Trial Aspirations (Pink Sheet)

• Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know (STAT)
• With Avidity and Pfizer, gene therapy enters a phase (STAT)
• Will Geron be acquired? The long-short view (STAT)
• 'Speed is everything': Versant-backed immunology startup raises $125M with plans for quick data (Endpoints)
• AbbVie banks on second-gen TL1A program, licensing antibody from FutureGen (Endpoints)
• UroGen touts long duration of response for its bladder cancer chemotherapy gel (Endpoints)
• Avidity’s $300M offering; Rapport raises $174M (Endpoints)
• Surprise flop for Cara’s oral pruritis drug forces company to cut its last R&D program (Endpoints)
• Barinthus Bio to lay off 25% of its workforce and focus on just two programs (Endpoints)

• Masimo embroiled in dual DOJ, SEC probes (MedTech Dive)
• Medline pulls thousands of endotracheal tubes due to risk of airway blockage (MedTech Dive)
• Philips launches stent system to restore blood flow in blocked veins (MedTech Dive)
• Kardium raises $104M to develop pulsed field ablation system (MedTech Dive)

• Melinda French Gates, going solo, aims to influence reproductive rights in the U.S. (STAT)
• Is $13B Devoted Health succeeding where other insurance upstarts have failed? (Endpoints)
• Elevance exec says Medicaid attrition has changed mix of members (Reuters)
• Guardant sues Tempus AI over DNA-testing patents (Reuters)
• Probiotics maker Seed Health explores $1 billion sale, sources say (Reuters)